Nasus Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of November 2025 for Nasus Pharma Ltd., a foreign private issuer headquartered in Tel Aviv, Israel. The report primarily discloses a significant change in executive leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
- Executive Appointment: On November 19, 2025, the Company appointed Mr. Eyal Rubin as Chief Financial Officer (CFO) and Executive Vice President.
- Employment Agreement: An Employment Agreement was executed on November 19, 2025. The Company expects to enter into a standard indemnification agreement with Mr. Rubin consistent with those for other directors and officers.
- Related Party Transactions: No related party transactions involving Mr. Rubin are required to be disclosed under Item 7.B of Form 20-F.
Management Commentary and Background
Mr. Rubin brings extensive experience in corporate finance and capital markets. His prior roles include:
- Protalix BioTherapeutics, Inc. (Sept 2019 – Oct 2025): Senior Vice President and CFO, leading corporate finance, accounting, and financial planning.
- BrainStorm Cell Therapeutics Inc. (Prior to Protalix): Executive Vice President and CFO, responsible for finance, accounting, and investor relations.
- Teva Pharmaceutical Industries Ltd. (Prior to BrainStorm): Vice President, Head of Corporate Treasury, managing cash operations and equity/debt capital markets transactions.
The Company issued a press release on November 20, 2025, titled "Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer," which is included as Exhibit 99.1.
Investor Verification Checklist
- Verify the terms of the Employment Agreement and the standard indemnification agreement to be executed with Mr. Rubin.
- Review the press release (Exhibit 99.1) for additional details on the leadership transition.
- Confirm that no undisclosed related party transactions exist involving the new CFO.
- Monitor future filings (e.g., Form 20-F) for the impact of this leadership change on financial strategy and capital markets activities.